Sanofi opens new Paris global headquarters

Sanofi (Euronext:SAN and Nasdaq:SNY) has announced that it has moved into its new international headquarters to Paris’s 17th arrondissement neighborhood, which is located on the right bank of the Seine River.  

The news headquarters, situated at 46-48 Avenue de la Grande Armée, was designed to promote novel ways to collaborate. 

Measuring 9,000 m² in area, the site, dubbed ‘La Maison Sanofi,’ will accommodate approximately 500 employees and meet stringent sustainability standards. 

“The opening of La Maison Sanofi is another step toward the modern healthcare company we strive to become. A company open to the world and that seeks to offer its people the best work environment to chase the miracles of science,” said Sanofi CEO Paul Hudson in a news release.

Sanofi headquarters

Sanofi notes that the new site reduces employees’ carbon footprint by half.  Read more

  • 0

Europe approves GSK and Sanofi’s next-gen COVID-19 booster vaccine VidPrevtyn Beta

The European Commission has approved the VidPrevtyn Beta COVID-19 vaccine as a booster for individuals who are at least 18.

The vaccine is the first next-gen protein-based adjuvanted COVID-19 booster to win European approval.

Sanofi (Nasdaq:SNY) developed the vaccine based on the beta variant using GSK’s (NYSE:GSK) pandemic adjuvant.

After announcing the news, Sanofi shares were up 1.45% to $43.97 in early afternoon trading. GSK shares were up 2.42% to $33.21.

VidPrevtyn Beta is a monovalent, recombinant-protein vaccine developed by Sanofi, modeled on the Beta variant and including GSK’s pandemic adjuvant. The vaccine uses recombinant-protein technology found in Sanofi’s seasonal flu vaccines.

In July, GSK and Sanofi announced that their adjuvanted bivalent version of its vaccine was 72% efficacious against omicron in adults in a Phase 3 study.

GSK and Sanofi noted that the vaccine performed well in registrational trials when the omi…

Read more
  • 0

Fall 2022 COVID-19 vaccine candidate tracker

[Photo from Pexels]

Approximately two-thirds of Americans have received at least one dose of a COVID-19 vaccine. 

But COVID-19 cases remain elevated following the spread of a series of omicron sublineages, which pose a threat to those vaccinated and naturally infected with various lineages of the coronavirus. 

A variety of companies are developing next-generation COVID-19 vaccines that could potentially optimize the strength and durability of immune protection compared to the first crop of vaccines. 

Here, we round up notable COVID-19 vaccine candidates that, at least, could help pave the way for the fall 2022 booster drive.

BNT162b5

Pfizer Inc. (NYSE:PFE) and BioNTech SE (Nasdaq:BNTX) are developing a bivalent COVID-19 vaccine candidate known as BNT162b5 based on the ancestral strain and a BA.1 Omicron variant. The vaccine has a modified spike protein design to optimize the immune response …

Read more
  • 0

Sanofi forms pharmacy fellowship program with Howard University

Sanofi today announced a collaboration with Howard University College of Pharmacy for a two-year post-professional Doctorate in Pharmacy fellowship program.

The collaboration is a part of the Cambridge, Massachusetts-based company’s ongoing efforts to address disparities in underrepresented communities. The goal is to hire fellows into permanent full-time positions at Sanofi.

The program will begin in the second half of the calendar year and will award 10 Pharma graduate students an opportunity to participate in practical learning experiences in various research and development field, including oncology, rare diseases, neurology, immunology, regulatory, pharmacovigilance, clinical and operations.

“At Sanofi, we recognize that workforce diversity correlates strongly with creativity, successful problem solving, and visionary innovation. This collaboration with Howard University will allow us the opportunity to foster the next generation of scie…

Read more
  • 0

Sanofi-GSK COVID-19 vaccine effective against omicron

GSK plc (LSE/NYSE:GSK) and Sanofi (NYSE:GSK) have announced that their adjuvanted bivalent vaccine candidate had 72% efficacy against omicron in adults in stage 2 of a Phase 3 study.

For those with SARS-CoV-2 seropositivity, the vaccine was 93.2% effective against omicron.

The vaccine is based on the original D614 virus and the beta (B.1.351) strain.

Across variants, the vaccine was 64.7% efficacious against symptomatic infection in adults. For those previously infected with COVID-19, the vaccine was 75.1% efficacious overall.

GSK and Sanofi noted that the vaccine candidate appeared to be well-tolerated.

Moderna (Nasdaq:MRNA) is developing a bivalent omicron booster vaccine candidate known as mRNA-1273.214.

Pfizer Inc. (NYSE:PFE) and its partner BioNTech SE (Nasdaq:BNTX) have released minimal data to date on their next-generation COVID-19 vaccine.

Sanofi’s and GSK’s Phase 3 COVID-19 clinical trial, dubbed VAT08, enrolled more …

Read more
  • 0

Sanofi-GSK next-generation COVID-19 booster could go head-to-head against revised Moderna and Pfizer offerings

Sanofi (Nasdaq:SNY) and GSK (NYSE:GSK) have announced that their next-generation COVID-19 booster vaccine candidate based on the beta variant yielded a substantial immune boost in adults previously primed with mRNA vaccines.

The novel vaccine yielded a strong increase in antibody titers above baseline against various variants of concern, including a 40-fold increase against the BA.1 omicron subvariant 15 days after vaccination. The same vaccine also yielded a 15-fold increase against the original D614 virus and a 30-fold increase against the beta strain.

The results were from two studies, the VAT02 Cohort 2 and COVIBOOST VAT013.

The new vaccine candidate elicited a more robust immune response than the Pfizer-BioNTech booster vaccine or the first-generation Sanofi-GSK vaccine candidate.

Last week, Moderna (Nasdaq:MRNA) also announced that its bivalent omicron booster vaccine candidate, mRNA-1273.214 yielded 1.75 times more neutralizing antibodies t…

Read more
  • 0

Sanofi unveils new campus in Massachusetts

Sanofi announced today that it is officially opening its new 900,000-square-foot campus at Cambridge Crossing in Cambridge, Massachusetts.

The new campus brings together 2,500 Sanofi Massachusetts-based employees in a shared space. The goal is to improve collaboration between R&D, Medical, and the Specialty Care business unit — and grow a science-centered, patient-focused culture. The Paris-based pharmaceutical company has a Play to Win strategy that focuses on growth, innovation, efficiency and reinvention.

Get the full story on our sister site Pharmaceutical Processing World. 

Read more
  • 0

Sanofi unveils new campus in Massachusetts

Sanofi announced today that it is officially opening its new 900,000-square-foot campus at Cambridge Crossing in Cambridge, Massachusetts.

The new campus brings together 2,500 Sanofi Massachusetts-based employees in a shared space. The goal is to improve collaboration between R&D, Medical, and the Specialty Care business unit — and grow a science-centered, patient-focused culture. The Paris-based pharmaceutical company has a Play to Win strategy that focuses on growth, innovation, efficiency and reinvention.

“Cambridge has been our home for many years. Opening our new facility in Cambridge Crossing is allowing us to bring together our employees across Massachusetts under one roof — which is an important step in facilitating the kind of collaboration needed to fulfill our purpose of chasing the miracles of science to improve people’s lives,” Bill Sibold, EVP and head of Global Specialty Care at Sanofi.

Dr. John Reed, EVP and global h…

Read more
  • 0

Regeneron purchases exclusive rights to Libtayo from Sanofi for $900M 

Sanofi (Nasdaq:SNY) has agreed to sell Regeneron (Nasdaq:REGN) exclusive international rights of Libtayo (cemiplimab) for $900 million. Sanofi will also receive an 11% royalty on global sales of the drug.

Libtayo is a monoclonal antibody targeting the immune checkpoint receptor PD-1 on T-cells.

Sanofi could also receive $100 million if the drug hits regulatory milestones in the next two years. The Paris-headquartered company could get an additional $100 million for meeting sales-related milestones in the same time window.

FDA approved the drug for advanced cutaneous squamous cell carcinoma in 2018. In 2021, Libtayo picked up indications for advanced basal cell carcinoma and first-line advanced non-small cell lung cancer with PD-L1 expression of at least 50%.

Sanofi and Regeneron entered into an international immuno-oncology alliance in 2015, agreeing then to split operating profits for Libtayo in the U.S. Sanofi agreed then to commercialize the dr…

Read more
  • 0

Digital therapeutics open up new opportunities in medicine

Pear Therapeutics designed the reSET prescription digital therapeutic for the treatment of substance abuse disorder. [Image courtesy of Pear Therapeutics]A wide range of companies are aiming to make waves through digital therapeutic offerings, and each is doing things differently.

“We are seeing tremendous momentum for the DTx industry, with more and more products coming to market and gaining commercial coverage and recent signals from the White House and Congress demonstrating their interest and recognition of DTx products as an important way to expand access to quality treatments for populations with public coverage, especially underserved communities,” Digital Therapeutics Alliance CEO Andy Molnar said via email. “While we are riding a massive swell, the wave hasn’t even begun to crest. The community is expanding and convening this broad coalition of stakeholders is critical to really scale the industry and drive DTx adoption and integration to truly transform healthc…

Read more
  • 0

Digital therapeutics open up new opportunities in medical design

A wide range of companies are aiming to make waves through digital therapeutic offerings and each is doing things differently.

“We are seeing tremendous momentum for the DTx industry, with more and more products coming to market and gaining commercial coverage and recent signals from the White House and Congress demonstrating their interest and recognition of DTx products as an important way to expand access to quality treatments for populations with public coverage, especially underserved communities,” Digital Therapeutics Alliance CEO Andy Molnar told Medical Design & Outsourcing. “While we are riding a massive swell, the wave hasn’t even begun to crest. The community is expanding and convening this broad coalition of stakeholders is critical to really scale the industry and drive DTx adoption and integration to truly transform healthcare.” 

Read: How DeepWell is developing video games as tools for treating me…

Read more
  • 0

Sanofi announces publication of early study of rilzabrutinib for immune thrombocytopenia

Sanofi (Nasdaq:SNY) has announced that the New England Journal of Medicine (NEJM) has published positive data from the Phase 1/2 dose-finding study testing the safety, pharmacokinetics and clinical activity of rilzabrutinib for immune thrombocytopenia.

Immune thrombocytopenia is associated with bruising and bleeding. Fewer than 200,000 Americans are diagnosed with the condition each year.

Rilzabrutinib is an experimental oral Bruton’s tyrosine kinase (BTK) inhibitor. The drug candidate has been the focus of about 20 clinical trials to date, with indications ranging from asthma to urticaria.

The study, published in NEJM, focused on adults with heavily pre-treated immune thrombocytopenia (ITP), concluded that rilzabrutinib therapy led to a rapid and durable increase in platelet count. Rilzabrutinib also appeared to have a good safety profile.

The drug candidate may increase platelet counts in patients with immune thrombocytopenia. As the NEJM articl…

Read more
  • 0